37 research outputs found
Assessing PDL-1 and PD-1 in NoneSmall Cell Lung Cancer: A Novel Immunoscore Approach
Published version. Source at http://dx.doi.org/10.1016/j.cllc.2016.09.009 Novel immune biomarkers could complement the TNM classification for nonesmall cell cancer (NSCLC),
improving the prognostic accuracy. The present study evaluated the prognostic significance of the immune
checkpoint molecules programmed cell death protein 1 (PD-1) and PD-1 ligand (PD-L1) in 536 patients with stage
I to IIIA NSCLC using an Immunoscore approach. Independently, and in combination, the infiltration of immune
cells expressing PD-L1 and PD-1 predicted patient survival, supplementing the TNM classification in each stage.
Introduction: Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or its ligand, PD-L1,
have gained momentum in the treatment of nonesmall cell lung cancer (NSCLC). However, their prognostic significance
remains controversial. The present study evaluated the expression of PD-L1 and PD-1 and their potential role in
an Immunoscore, supplementing the TNM classification of NSCLC. Materials and Methods: Tissue microarrays
constructed from tumor tissue samples from 2 cohorts of a total of 536 patients (University Hospital of North Norway,
n ¼ 285; Nordland Hospital, n ¼ 251) with primary resected stage I to IIIA NSCLC. PD-L1 and PD-1 were evaluated by
immunohistochemistry in the primary tumor and metastatic lymph node tissue. Results: In univariate analysis, a high
density of PD-L1þ immune cells in the stromal compartment (S-PD-L1) and PD-1þ intraepithelial tumor infiltrating
lymphocytes (T-PD-1) was associated with favorable disease-specific survival (DSS; S-PD-L1, P ¼ .004; T-PD-1, P ¼
.012), both limited to the squamous cell carcinoma histologic subgroup (S-PD-L1, P ¼ .002; T-PD-1, P ¼ .034). A
combined low S-PD-L1 and T-PD-1 was associated with poor survival in all patients (DSS: hazard ratio [HR], 1.81;
95% confidence interval [CI], 1.37-2.40; P < .001) at both centers and for all pathologic stages. In multivariate analysis,
S-PD-L1 and T-PD-1 were independent positive prognostic factors, and combined low scores remained an independent
prognosticator for poor survival (DSS: HR, 1.72; 95% CI, 1.29-2.28; P < .001; disease-free survival, P ¼ .001;
overall survival, P ¼ .005). Conclusion: Our study identified S-PD-L1 and T-PD-1 as independent positive prognostic
factors for NSCLC patients. Their combination added significant prognostic impact within each pathologic stage and
hence are feasible to include in a TNM Immunoscore
The prognostic effect of KRAS mutations in non-small cell lung carcinoma revisited: A norwegian multicentre study
Background: due to emerging therapeutics targeting KRAS G12C and previous reports with conflicting results regarding the prognostic impact of KRAS and KRAS G12C in non-small cell lung cancer (NSCLC), we aimed to investigate the frequency of KRAS mutations and their associations with clinical characteristics and outcome. Since mutation subtypes have different preferences for downstream pathways, we also aimed to investigate whether there were differences in outcome according to mutation preference for the Raf, PI3K/Akt, or RalGDS/Ral pathways. Methods: retrospectively, clinicopathological data from 1233 stage I–IV non-squamous NSCLC patients with known KRAS status were reviewed. KRAS’ associations with clinical characteristics were analysed. Progression free survival (PFS) and overall survival (OS) were assessed for the following groups: KRAS wild type (wt) versus mutated, KRAS wt versus KRAS G12C versus KRAS non-G12C, among KRAS mutation subtypes and among mutation subtypes grouped according to preference for downstream pathways. Results: a total of 1117 patients were included; 38% had KRAS mutated tumours, 17% had G12C. Among KRAS mutated, G12C was the most frequent mutation in former/current smokers (45%) and G12D in never smokers (46%). There were no significant differences in survival according to KRAS status, G12C status, among KRAS mutation subtypes or mutation preference for downstream pathways. Conclusion: KRAS status or KRAS mutation subtype did not have any significant influence on PFS or OS
A four-surface schematic eye of macaque monkey obtained by an optical method
AbstractSchematic eyes for four Macaca fascicularis monkeys were constructed from measurements of the positions and curvatures of the anterior and posterior surfaces of the cornea and lens. All of these measurements were obtained from Scheimpflug photography through the use of a ray-tracing analysis. Some of these measurements were also checked (and confirmed) by keratometry and ultrasound. Gaussian lens equations were applied to the measured dimensions of each individual eye in order to construct schematic eyes. The mean total power predicted by the schematic eyes agreed closely with independent measurements based on retinoscopy and ultrasound results, 74.2 ± 1.3 (SEM) vs 74.7 ± 0.3 (SEM) diopters. The predicted magnification of 202 μm/deg in one eye was confirmed by direct measurement of 205 μm/deg for a foveal laser lesion. The mean foveal retinal magnification calculated for our eight schematic eyes was 211 ± (SEM) μm/deg, slightly less than the value obtained by application of the method of Rolls and Cowey [Experimental Brain Research, 10, 298–310 (1970)] to our eight eyes but just 4% more than the value obtained by application of the method of Perry and Cowey [Vision Research, 12, 1795–1810 (1985)]
Hypertensive svangerskapskomplikasjoner. Et litteraturstudium basert på Kola Birth Registry
Immunological markers in non-small cell lung cancer (NSCLC)
The paper III of this thesis is not available in Munin.
Paper III: Paulsen, E. E., Kilvaer, T. K., Khanehkenari, M. R., Richardsen, E., Hald, S. M., Andersen, S., Busund, L-T., Bremnes,
R. M., Donnem, T.: “CTLA-4 expression in the NSCLC tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases”. (Manuscript).Lung cancer is the leading cause of cancer-related mortality worldwide, and novel prognostic factors supplementing the TNM classification are needed. The type, density and location of immune cell subsets in the tumor microenvironment (“Immunoscore”) may influence patient outcome in cancers, including non-small cell lung cancer (NSCLC). Tumor infiltrating cytotoxic (CD8+) T cells, the major anticancer effector cells, are predictive of improved prognoses in NSCLC. The importance of memory T cells (CD45RO+), which can provide long-term antitumor response, is uncertain in NSCLC. Drugs targeting “Immune checkpoints”, which negatively regulate T cell activation and function (e.g. CTLA-4 and PD-1/PD-L1), have impressive efficacy in some NSCLC patients, but the prognostic impact of immune checkpoint molecules in NSCLC is disputed.
We aimed to investigate the prognostic impact of important immune markers (CD45RO, CD8, PD-1, PD-L1 and CTLA-4) in NSCLC. We constructed tissue microarrays from primary tumors and metastatic lymph nodes retrospectively collected from 536 surgically treated stage I-IIIA NSCLC patients. By immunohistochemistry, we evaluated the in situ expression of the immune markers of malignant and non-malignant cells in the NSCLC tumor microenvironment.
We demonstrated that infiltration by CD45RO+ T cells was a robust prognosticator of improved survival in NSCLC patients with squamous cell carcinoma (SCC), especially when combined with CD8+ T cells. The combined score is a candidate for inclusion in a NSCLC Immunoscore, supplementing the TNM-classification in SCC patients. Overexpression of PD-1/PD-L1 in immune cells of SCC primary tumors was independently associated with a positive prognosis in all pathological stages, apparently reflecting the presence of an activated immune system. CTLA-4 expression was an independent negative prognostic factor in lymph node metastasis only.
Our studies highlight differences between NSCLC histological subgroups and heterogeneity between primary tumors and corresponding metastases, and identified novel prognostic factors which may improve prognostic accuracy for NSCLC subgroups
Digitally quantified CD8+ cells: the best candidate marker for an immune cell score in non-small cell lung cancer?
The TNM classification is well established as a state-of-the-art prognostic and treatment-decision-making tool for non-small cell lung cancer (NSCLC) patients. However, incorporation of biological data may hone the TNM system. This article focuses on choosing and incorporating subsets of tissue-infiltrating lymphocyte (TIL), detected by specific immunohistochemistry and automatically quantified by open source software, into a TNM-Immune cell score (TNM-I) for NSCLC. We use common markers (CD3, CD4, CD8, CD20 and CD45RO) of TILs to identify TIL subsets in tissue micro-arrays comprising tumor tissue from 553 patients resected for primary NSCLC. The number of TILs is automatically quantified using open source software (QuPath). Their prognostic efficacy, alone and within a TNM-I model, is evaluated in all patients and histological subgroups. Compared with previous manual semi-quantitative scoring of TILs in the same cohort, the present digital quantification proved superior. As a proof-of-concept, we construct a TNM-I, using TNM categories and the CD8+ TIL density. The TNM-I is an independent prognosticator of favorable diagnosis in both the overall cohort and in the main histological subgroups. In conclusion, CD8+ TIL density is the most promising candidate marker for a TNM-I in NSCLC. The prognostic efficacy of the CD8+ TIL density is strongest in lung squamous cell carcinomas, whereas both CD8+ TILs and CD20+ TILs, or a combination of these, may be candidates for a TNM-I in lung adenocarcinoma. Furthermore, based on the presented results, digital quantification is the preferred method for scoring TILs in the future
Impact of microvessel patterns and immune status in NSCLC: a non-angiogenic vasculature is an independent negative prognostic factor in lung adenocarcinoma
Introduction: Non-small cell lung carcinomas (NSCLC) exhibit different microvessel patterns (MVPs). Basal (BA), diffuse (DA) and papillary (PA) patterns show signs of angiogenesis (new blood vessels), while an alveolar pattern indicates that tumors are co-opting existing normal vessels (non-angiogenic alveolar, NAA). NAA tumor growth is known to exist in NSCLC, but little is known about its prognostic impact in different histological subgroups, and about associations between MVPs and immune cell infiltration.
Methods: Detailed patterns of angiogenic and non-angiogenic tumor growth were evaluated by CD34 immunohistochemistry in whole tissue slides from 553 surgically treated patients with NSCLC stage I-IIIB disease. Associations with clinicopathological variables and markers related to tumor immunology-, angiogenesis- and hypoxia/metabolism were explored, and disease-specific survival (DSS) was analyzed according to histological subtypes.
Results: The predominant MVP was angiogenic in 82% of tumors: BA 40%, DA 34%, PA 8%, while a NAA pattern dominated in 18%. A contribution of the NAA pattern >5% (NAA+), i.e., either dominant or minority, was observed in 40.1% of tumors and was associated with poor disease-specific survival (DSS) (p=0.015). When stratified by histology, a significantly decreased DSS for NAA+ was found for adenocarcinomas (LUAD) only (p
Conclusion: The NAA+ pattern is an independent poor prognostic factor in LUAD. In NAA+ tumors, several immunological markers add prognostic impact in LUSC but not in LUAD
CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases
The immune checkpoint receptor CTLA-4 plays a crucial part in negatively regulating T cell activation and maintaining self-tolerance. It is frequently overexpressed in a variety of malignancies, yet its prognostic impact in non-small cell lung cancer (NSCLC) remains unclear. We constructed tissue microarrays from tumor tissue samples and evaluated the immunohistochemical expression of CTLA-4 in 536 patients with primary resected stage I–IIIA NSCLC. Expression of CTLA-4 was analyzed in tumor and stromal primary tumor tissue and in locoregional metastatic lymph nodes. CTLA-4 expression in neither tumor epithelial cells (T-CTLA-4) nor stromal cells (S-CTLA-4) of primary tumors was significantly associated with disease-specific survival (DSS) in all patients. However, high S-CTLA-4 expression independently predicted significantly improved DSS in the squamous cell carcinoma subgroup (HR 0.62, 95% CI 0.41–0.93, P = 0.021). In contrast, there was an independent negative prognostic impact of T-CTLA-4 expression in metastatic lymph nodes (HR 1.65, 95% CI 1.03–2.65, P = 0.039). Our results indicate that the expression of CTLA-4 has diverging prognostic impacts in metastatic NSCLC lymph nodes versus primary tumors. The presented results highlight important differences in the tumor microenvironments of primary and metastatic NSCLC tissues, and have potential to guide treatment and clinical sampling strategies
Prognostic effect of intratumoral neutrophils across histological subtypes of non-small cell lung cancer
Recent data indicate that tumor-associated neutrophils (TANs) serve a dual role in tumor progression and regression. CD66b is a neutrophil marker and has been associated with patient outcome in various cancers. However, its clinical impact in non-small cell lung cancer (NSCLC) remains controversial. 536 NSCLC patients, of which 172 harbored lymph node metastases, were included in this study. Tissue microarrays were constructed and multiplexed immunohistochemistry of CD66b, CD34 and pan-keratin was performed to evaluate the localization and quantity of CD66b+ TANs. High intratumoral CD66b+ TANs density in squamous cell carcinoma (SCC) subgroup was an independent positive prognosticator for disease-specific survival (P = 0.038). In contrast, high intratumoral TANs density was an independent negative prognostic factor in the adenocarcinoma (ADC) subgroup (P= 0.032). Likewise, in ADC patients with lymph node metastases, high level of intratumoral TANs was associated with poor prognosis (P = 0.003). Stromal CD66b+ TANs were not associated with outcome of NSCLC patients. In conclusion, CD66b+ TANs show diverging prognostic effect in NSCLC patients according to histological subgroups. The presence of CD66b+ TANs could prove pivotal for development of an immunoscore in ADC NSCLC patients
Cancer associated fibroblasts in stage I-IIIA NSCLC: Prognostic impact and their correlations with tumor molecular markers
Background
Cancer Associated Fibroblasts (CAFs) are thought to regulate tumor growth and metastasis.
Fibroblast Activating Protein 1 (FAP-1) is a marker for fibroblast activation and by many
recognized as the main marker of CAFs. Alpha Smooth Muscle Actin (α-SMA) is a general
myofibroblast marker, and can be used to identify CAFs. This study investigates the prognostic
impact of FAP-1 and α-SMA in non-small cell lung cancer (NSCLC) patients and correlates
their expression to 105 proteins investigated in the same cohort.
Methods
Tumor specimens from 536 NSCLC patients were obtained and tissue micro-arrays were
constructed. Immunohistochemistry was used to evaluate the expression of FAP-1 and α-
SMA and explore their impact on survival and association with other tumor molecular markers
in NSCLC patients.
Results
High expression of FAP-1, but not α-SMA, in squamous cell carcinoma (SCC, P = 0.043,
HR = 0.63 95% CI 0.40–0.99) was significantly associated with increased disease-specific
survival. FAP-1 and α-SMA were not significantly correlated to each other. Analyses of
FAP-1 and α-SMA associated with other tumor-related proteins revealed histotype-specific
correlation patterns.
Conclusion
The presence of FAP-1 expressing CAFs is an indicator of positive outcome for NSCLCSCC
patients. In addition, correlation analyses suggest FAP-1 and α-SMA to label different subsets of fibroblasts and their associations with other tumor-related proteins diverge
according to histological subtype